Lebrikizumab for Idiopathic Pulmonary Fibrosis

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

pf_lebrizikumab

Lebrikizumab is an experimental drug aimed at treating inflammatory and fibrotic diseases. Owing to its immunosuppressive potential, it has been tested against diseases like asthma and refractory Hodgkin’s Lymphoma with successful results. Currently, the company is also pursuing studies to test its use in Idiopathic Pulmonary Fibrosis.

Lebrikizumab was first developed by Texas-based biopharmaceutical company Tanox under the name TNX-650. Genentech acquired Tanox in 2007 and initiated successful clinical trials, testing the therapy in refractory Hodgkin’s Lymphoma and asthma.

 

Read more about it: http://bit.ly/1l7hj1n

Print This Page

About the Author

Marta Ribeiro avatar
Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.

Tags

Idiopathic pulmonary fibrosis (IPF), Lebrikizumab

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums

Recent Posts


Recommended reading